IRVAN syndrome

IRVAN syndrome is a rare idiopathic retinal vasculitis characterized by the triad of retinal vasculitis, aneurysmal dilations at arterial bifurcations, and neuroretinitis. The acronym IRVAN stands for Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis. This condition primarily affects the eyes and can lead to severe visual impairment if left untreated. The hallmark feature is the presence of macroaneurysms occurring at retinal arterial bifurcations, which distinguishes it from other forms of retinal vasculitis. Additional features may include peripheral retinal capillary nonperfusion, retinal neovascularization, vitreous hemorrhage, anterior uveitis, and macular exudation. The disease predominantly affects young to middle-aged adults and appears to be more common in women. The exact cause of IRVAN syndrome remains unknown, and no systemic disease association has been consistently identified, though some cases have been reported in association with other inflammatory conditions. The disease can be unilateral or bilateral and tends to be progressive without treatment. Early diagnosis is critical, as timely intervention can help preserve vision. Treatment primarily involves laser photocoagulation (both panretinal and focal) to address areas of retinal nonperfusion and neovascularization, which has been shown to stabilize or improve visual outcomes in many patients. Anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections have also been used as adjunctive therapy, particularly for macular edema and neovascularization. Corticosteroids may be employed to manage the inflammatory component. Despite treatment, some patients may experience progressive visual loss due to complications such as vitreous hemorrhage, tractional retinal detachment, or macular ischemia.

Common questions about IRVAN syndrome